Synlogic announces initiation of Synpheny-3 global, pivotal phase 3 study evaluating SYNB1934 for PKU

Date：2023-06-05

Jun 5, 2023 — Registrational study designed to support BLA submission of first-in-class biotherapeutic.

CommBio Therapeutics Co., Ltd 沪ICP备2021004953号-1